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Background: The effect of the addition of fotemustine and/or interferon (IFN) to standard therapy with
dacarbazine alone in patients with advanced malignant melanoma was investigated in a multicenter, randomized
2x2 factorial design trial.
Methods: A total of 260 patients were randomly assigned to one of four treatment groups: (A) fotemustine and
dacarbazine repeated on 3-week cycle; (B) same treatment as (A) plus IFN-α2b three times per week; (C)
dacarbazine alone repeated on 3-week cycle; (D) same treatment as (C) plus IFN-α2b three times per week. Two
comparisons were planned to assess the efficacy of fotemustine (groups A+B vs. C+D) and IFN-α2b
(groups A+C vs. B+D).
Results: Addition of fotemustine did not significantly improve overall survival (OS) (p=0.28) or progression-free
survival (PFS) (p=0.55); Hazard ratio (HR) for OS was 0.93 (95% CI 0.71-1.21). Similarly, addition of IFN-α2b did not
improve OS (p=0.68) or PFS (p=0.65); HR for OS was 0.92 (95% CI 0.70-1.20). Overall response rate was not improved
by the addition of either fotemustine (p=0.87) or IFN-α2b (p=0.57). The combination of all three drugs resulted in
the highest occurrence of adverse events.
Conclusions: No significant improvement in outcomes were observed with the addition of either fotemustine or
IFN-α2b to dacarbazine.
Trial registration: ClinicalTrials.gov: NCT01359956
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The incidence of cutaneous melanoma has risen rapidly
over the last 30 years, with an annual rate increase among
the Caucasian population of approximately 3%. Melanoma
is now the third most prevalent cancer, representing about
7% of tumors in both men and women. The median age at
diagnosis for melanoma is 63 years in men and 56 years for
women. Although melanoma is rare before the age of
30 years, it is the second and third most commonly* Correspondence: paolo.ascierto@gmail.com
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reproduction in any medium, provided the ordiagnosed cancer in women and men, respectively, in the
20 to 29 years age group. The 5-year and 10-year relative
survival rates for patients with melanoma are 91.2% and
89.1%, respectively. For those with localized melanoma, the
5-year survival rate is 98.2%; 5-year survival rates for indivi-
duals with regional and distant stage disease decline to
61.7% and 15.2%, respectively [1].
Treatment options for patients with advanced melanoma
are limited and non-curative in the majority of cases. In a
meta-analysis of 42 phase II trials including more than
2100 patients, the median survival time was 6.2 months
[95% confidence interval (CI), 5.9−6.5 months), with 25.5%
of the patients (95% CI, 23.6−27.4%) alive at 1 year [2].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(95%CI, 1.6−1.8 months), with 14.5% of the patients (95%
CI, 12.9−16.1%) progression-free at 6 months.
Dacarbazine (DTIC) was the first approved che-
motherapeutic agent for the treatment of metastatic
melanoma and, for more than 30 years, was the standard
treatment for such disease. Fotemustine is the most ac-
tive nitrosourea in metastatic melanoma, with an object-
ive response rate of 20–25%, with 5–8% of complete
responses, and was the first drug to show significant effi-
cacy in brain metastases [3,4]. One hypothesis to explain
this is that fotemustine, thanks to the phosphoalanine
group, is highly lipophilic and so able to diffuse across
the blood–brain barrier. Another explanation could be
the potential effect of fotemustine in inhibiting vascular
endothelial growth factor (VEGF)-C release and thereby
reducing tumor diffusion [5]. In a phase III study, fote-
mustine was associated with a higher overall response
rate (ORR) than dacarbazine in the intention-to-treat
(ITT) population (15.2% vs 6.8%, p=0.043). However, the
response duration (time to disease progression and over-
all survival [OS]) was not statistically significantly differ-
ent between groups [6].
Interferon-α (IFN) has been suggested to exert activity
against melanoma through immunomodulatory mechan-
isms [7], although it also has an anti-proliferative effect. Evi-
dence for the involvement of different immunomodulatory
mechanisms has been derived from several studies which
have shown an increase in tumor infiltrating cells [8], the
development of autoantibodies and clinical manifestations
of autoimmunity (~30%) [9,10], a decrease in circulating
Treg cells [11], modulation of the STAT1/STAT3 balance
in tumor cells and host lymphocytes [12], changes in serum
cytokine concentrations [13], and normalization of T-cell
signaling defects in peripheral blood lymphocytes [14,15].
In the adjuvant setting, a meta-analysis of randomized
melanoma trials using a wide range of IFN dose regimens
revealed that the benefits of IFN are independent of dose
or therapy duration, and translate into an absolute OS
benefit of approximately 3% (95% CI: 1–5%) at 5 years
[16,17].
In our previous experience [18], 43 patients with
advanced melanoma received first-line therapy with a
combination of fotemustine 100 mg/m2 on day 1,
intravenous (IV) dacarbazine 250 mg/m2 on days
2–5 every three weeks, and subcutaneous (SC) α2a 3
MIU three times a week until progression. The ORR was
40% (95% CI, 25-56%), and the median duration of re-
sponse was 24 weeks. Median survival time was
40 weeks, with a 13% 2-year survival rate. Similar results
(ORR, 38.3% [95% CI, 26.1–51.8%], median duration of
response, 28 weeks; median survival, 36 weeks) were
observed in a subsequent study in which cisplatin was
added to fotemustine, dacarbazine and IFN [19],suggesting the addition of cisplatin was not clinically
beneficial. In both these studies, some patients achieved
a durable complete response (CR). On this basis, and
supported by findings from other studies [20], we con-
sidered that IFN may have contributed to prolonging the
median duration of response (by about 6 months in both
studies).
In this prospective, randomized, controlled study, we
assessed the effect of adding fotemustine and/or IFN to




This multicenter, randomized, open-label, 2×2 factorial
phase III trial (ClinicalTrials.gov NCT01359956) com-
pared fotemustine and dacarbazine versus dacarbazine
with or without the addition of α in patients with
advanced malignant melanoma. The study was designed,
co-ordinated and conducted independently by the inves-
tigators and was approved by the Ethical Committees of
participating institutions.
Adult (>18 years old) patients with malignant melanoma
(histologically confirmed) in advanced stage or recurrent
after surgery, ECOG performance status (PS) 0–2 and not
amenable to further surgery or local therapy were eligible if
they had adequate bone marrow function, normal liver and
renal function, a life expectancy greater than 3 months and
no prior surgery in the previous 3 weeks. Only untreated
patients were eligible. Palliative radiation, if required, could
be performed before starting chemotherapy. If palliative ra-
diation was required during the study, the patient was per-
manently discontinued from further treatment. Female
patients were eligible if they were not pregnant or lactating.
Patients with known HIV disease, other previous or con-
current malignancies (except for surgically cured carcinoma
in-situ of the cervix and basal or squamous cell carcinoma
of the skin), prior chemo-immunotherapy, concurrent
treatment with other experimental drugs, chemotherapy,
immunotherapy, hormone therapy and radiation therapy
were excluded. All patients provided written informed
consent.
Patients were randomly assigned to one of four treat-
ment groups: (A) fotemustine 100 mg/m2 IV on day 1
and dacarbazine 900 mg/m2 IV on day 2 repeated on a
three-week cycle; (B) same treatment as (A) plus α2b 5
MUI three times per week; (C) dacarbazine alone
900 mg/m2 IV on day 1 repeated on a three-week cycle;
(D) same treatment as (C) plus α2b 5 MUI three times
per week. Patients were randomized through a compu-
terized procedure of permuted blocks centralized at the
coordinating center (Medical Oncology, NCI Napoli),
stratified by PS (0–1,2) and site of metastases (visceral,
not visceral).
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tected from light) as a 1-hour infusion and dacarbazine
was delivered in 500 ml of saline solution by a 1-hour
infusion. Antiemetic prophylaxis with 5-HT3 receptor
antagonists was routinely used. Courses were repeated
every three weeks. After three cycles, a rest period of five
weeks was required to ensure complete hematological
recovery. Disease assessment (measurement of all tumor
lesions) was performed by CT scan before receiving
therapy, every three cycles, at the end of treatment and
every three months during the follow-up period.
Statistical analysis
To identify a hazard ratio (HR) of 0.65 for each of the
two comparisons, with a two-tailed type I error α=5%
and a type II error β=10% (power = 90%), 227 deaths
were needed and 270 patients were planned to be en-
rolled. These assumptions were based on two our previ-
ous phase II trials [18,19].
Two comparisons were planned, combining the treat-
ment groups in a 2x2 manner: (i) to assess the efficacy of
fotemustine, groups A + B were compared with groups C +
D; and (ii) to assess the efficacy of IFN, groups A + C were
compared with groups B + D. Accordingly, except for base-
line values, results are reported separately for the two
comparisons.
The primary endpoint was OS, defined as the time
from the date of randomisation to the date of death
from any cause, or the date of last follow-up for living
patients. Secondary end points were PFS, response, and
toxicity. PFS was defined as the time from the date of
randomisation to the date of progression of disease or
death from any cause, whichever occurred first, or date
of last follow-up for patients without progression and
alive at the end of the study. Best response was defined
according to the WHO criteria [21] and was assessed
every three courses during treatment. CR was defined as
disappearance of all symptoms and signs of all measur-
able disease, lasting for at least four weeks, without ap-
pearance of new lesions. Partial response (PR) was
defined as a >50% reduction in the sum of the products
of the perpendicular diameters of all measurable lesions,
lasting for at least four weeks, without appearance of
new lesions or enlargement of existing lesions. Progres-
sive disease (PD) was defined as an increase in the prod-
uct of two perpendicular diameters of any measured
lesion by >25% over the size present at entry on study,
or the appearance of new lesions. All other patients were
considered to have stable disease (SD). Overall response
rate (ORR) included CR and PR. Toxicity was scored
according to the WHO classification [21], with events
recorded as per the worst severity for each patient.
All efficacy analyses were done on an ITT basis. Sig-
nificance level was 0.05 (two-tailed) without adjustmentfor multiple comparisons. OS and PFS curves were esti-
mated with the Kaplan-Meier (K-M) method, and treat-
ments were compared with a two-sided log-rank test.
HR and 95% CIs were estimated by a Cox proportional
hazards model that included treatment, gender, PS, site
of metastases, Breslow score and the other treatment
factor as covariates. Further exploratory analyses of OS
were planned for predefined subgroups of patients.
Contingency tables and χ2 test were applied in the as-
sessment of response. All patients who received at least
one dose of treatment were included in the statistical
analysis of toxicity: first, an exact linear permutation test
was applied to compare all toxicity grades, second, an
exact χ2 test was applied that compared severe
(grades 3–5) versus not severe (grades 0–2) toxicity.
Results
Patients
A total of 269 patients with advanced malignant melanoma
were randomized between March 2002 and July 2007.
Nine patients were lost to follow-up immediately after
randomization. Five patients received different treatment
from that assigned. One patient was found to be ineligible
after randomization. All the patients, with the exclusion of
those lost after randomization for which no information
was available, were analyzed according to the ITTapproach.
Participant flow is described in Figure 1.
Baseline characteristics of the 260 patients were generally
similar across the four treatment arms, although minor dif-
ferences were observed in adjuvant immunotherapy, LDH
and presence of brain metastases (Table 1). Median age of
patients was 55 years (mean ± SD, 55 ± 15 years). Almost
all patients had a PS of 0–1 and almost half had a Breslow
score between 2 and 4. Most patients were classified as
M1C with regard to metastatic site.
154 out the 260 patients discontinued the treatment in
the first three cycles, mostly because of progression
(74%) or death (17%). Only in five case (3%) treatment
was discontinued because of toxicity or refusal, mainly
in the three-drug arm.
Efficacy analysis
All 260 patients were included in the efficacy analyses.
Overall, 250 deaths and 253 disease progressions were
observed. K-M curves of the four treatment arms are
shown in Figure 2 for OS (upper panel) and PFS (lower
panel). Results of the efficacy analysis are reported in
Table 2.
Fotemustine
Median OS was 7.9 months (95% CI 6.6−10.2) for patients
receiving fotemustine (groups A + B) compared with
8.6 months (95% CI 6.3−10.4) without fotemustine (groups
C + D) (p=0.28). Median PFS was 2.7 months (95% CI 2.4
Figure 1 Study flow diagram according to CONSORT.
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(p=0.55) without. In multivariate analysis, adjusted for age,
sex, PS, site of metastases, Breslow score and IFN treat-
ment, HR of death and disease progression for patients
treated with fotemustine were 0.93 (95% CI 0.71−1.21) and
0.93 (95% CI 0.72−1.21), respectively. No significant differ-
ence was seen in ORR between patients who were treated
with fotemustine and those who were not (24% [95% CI 17
−32%] versus 26% [95% CI 18−33%], p=0.87).
IFN-α2b
Median OS was 9.1 months (95% CI 6.3−11.1) with α2b
(groups B + D) and 7.7 months (95% CI 6.3−9.7) without
(groups A + C) (p=0.68). Median PFS was 2.8 months
(95% CI 2.4−3.9) in α2b-treated patients compared with
2.5 months (95% CI 2.3−2.9) without α2b (p=0.28). In
multivariate analysis, HR of death and progression for
patients treated with α2b were 0.92 (95% CI 0.70−1.20)
and 0.96 (95% CI 0.73−1.25), respectively. ORR was 27%
(95% CI 19−35%) in patients who received α2b com-
pared with 23% (95% CI 16−30%) in patients who did
not (p=0.57).
Results of univariate analyses of OS in predefined sub-
groups of subjects for the two comparisons are reported
in Figure 3. No evidence of heterogeneity was suggested
by these results, except for age, where increased efficacy
in younger subjects was observed both for fotemustine(p=0.015 at interaction test) and α2b (p<0.001 at inter-
action test).
Adverse events are reported in Table 3. Overall, a
greater number of toxic effects were reported in patients
who received all three drugs (Group B). Patients given
fotemustine had a significantly higher incidence of
anemia and platelet reduction, although the worst degree
was generally not severe. Patients given α2b had a
significantly higher incidence of neutropenia, anemia
and fever. However, similarly to fotemustine, the worst
reported degree was not usually severe.
Discussion
In this randomized trial we did not find any significant
improvement in PFS, OS or ORR with the addition of ei-
ther fotemustine or IFN-α2b to dacarbazine. The ab-
sence of any possible synergism between dacarbazine
and fotemustine in our study is consistent with other
studies of combination chemotherapy in advanced mel-
anoma. Moreover, there does not appear to be any po-
tential delaying effect on the occurrence of brain
metastases through the addition of fotemustine, as was
reported by Avril et al. [6]. Moreover, despite our prelim-
inary results which suggested a potential benefit of IFN
[18,19], its addition did not improve outcomes in this study.
Therefore, the combination of IFN, as immunomodulating
and/or anti-proliferative agent, and chemotherapy in the
Table 1 Baseline characteristics of patients by treatment arm
Variable FM+DTIC FM+DTIC+IFN DTIC DTIC+IFN Total
(N=64) (N=68) (N=70) (N=58) (N=260)
Male gender 42 (66%) 35 (51%) 42 (60%) 38 (66%) 157 (60%)
Age years, mean (SD) 54 (13) 50 (15) 59 (15) 56 (14) 55 (15)
Adjuvant immunotherapy
Yes 20 (31%) 24 (35%) 21 (30%) 8 (14%) 73 (28%)
No 43 (67%) 43 (63%) 49 (70%) 49 (84%) 184 (71%)
Missing 1 (2%) 1 (1%) 0 (0%) 1 (2%) 3 (1%)
Performance Status
0 45 (70%) 52 (76%) 55 (79%) 41 (71%) 193 (74%)
1 16 (25%) 12 (18%) 14 (20%) 15 (26%) 57 (22%)
2 2 (3%) 4 (6%) 1 (1%) 1 (2%) 8 (3%)
Missing 1 (2%) 0 (0%) 0 (0%) 1 (2%) 2 (1%)
Histology
Superficial spreading melanoma 13 (20%) 8 (12%) 7 (10%) 6 (10%) 34 (13%)
Nodular melanoma 27 (42%) 36 (53%) 36 (51%) 31 (53%) 130 (50%)
Lentigo malignant melanoma 0 (0%) 0 (0%) 1 (1%) 0 (0%) 1 (0%)
Acral lentiginous melanoma 1 (2%) 2 (3%) 5 (7%) 1 (2%) 9 (3%)
Other 22 (34%) 22 (32%) 21 (30%) 19 (33%) 84 (32%)
Missing 1 (2%) 0 (0%) 0 (0%) 1 (2%) 2 (1%)
Breslow
<2 18 (28%) 17 (25%) 10 (14%) 10 (17%) 55 (21%)
≥2 and ≤4 30 (47%) 27 (40%) 36 (51%) 28 (48%) 121 (47%)
>4 15 (23%) 24 (35%) 24 (34%) 20 (34%) 83 (32%)
Unknown 1 (2%) 0 (0%) 0 (0%) 0 (0%) 1 (0%)
Ulceration
Yes 28 (44%) 27 (40%) 28 (40%) 24 (41%) 107 (41%)
No 23 (36%) 29 (43%) 35 (50%) 27 (47%) 114 (44%)
Unknown 13 (20%) 12 (18%) 7 (10%) 7 (12%) 39 (15%)
LDH
Normal 28 (44%) 31 (46%) 23 (33%) 17 (29%) 99 (38%)
>1 UNL and ≤ 2UNL 25 (39%) 24 (35%) 19 (27%) 22 (38%) 90 (35%)
>2 UNL 11 (17%) 13 (19%) 28 (40%) 19 (33%) 71 (27%)
Visceral disease
Yes 51 (80%) 49 (72%) 53 (76%) 47 (81%) 200 (77%)
No 12 (19%) 19 (30%) 17 (24%) 10 (17%) 58 (22%)
Missing 1 (2%) 0 (0%) 0 (0%) 1 (2%) 2 (1%)
Site of metastases
M1A 6 (9%) 11 (16%) 6 (9%) 3 (5%) 26 (10%)
M1B 8 (12%) 2 (3%) 7 (10%) 4 (7%) 21 (8%)
M1C 49 (77%) 55 (81%) 57 (81%) 50 (86%) 211 (81%)
Missing 1 (2%) 0 (0%) 0 (0%) 1 (2%) 2 (1%)
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Figure 2 Kaplan-Meier curves of the four treatment arms: overall survival (upper panel) and progression-free survival (lower panel).
Table 1 Baseline characteristics of patients by treatment arm (Continued)
Brain metastases
Yes 11 (17%) 13 (19%) 4 (6%) 5 (9%) 33 (13%)
No 53 (83%) 55 (81%) 66 (94%) 53 (91%) 227 (87%)
Data are reported as absolute numbers (%), except for age (mean and standard deviation).
FM = fotemustine; DTIC = dacarbazine; IFN = interferon-α2b.
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Table 2 Efficacy outcomes











Events, n (%) 125 (95%) 125 (98%) 122 (97%) 128 (96%)
Median, months (95% CI) 7.9 (6.6−10.2) 8.6 (6.3−10.4) 0.93 (0.71
−1.21)




Events, n (%) 128 (97%) 125 (98%) 123 (98%) 130 (97%)
Median, months (95% CI) 2.7 (2.4−3.8) 2.5 (2.3−3.7) 0.93 (0.72
−1.21)
2.8 (2.4−3.9) 2.5 (2.3−2.9) 0.96 (0.73
−1.25)
Overall response, n (%) 32 (34%) 33 (26%) 34 (27%) 31 (23%)
(95% CI) (17−32%) (18−33%) (19−35%) (16−30%)
* After adjustment by age, sex, performance status, site of metastases, Breslow score and other treatment factor.
FM = fotemustine; DTIC = dacarbazine; IFN = interferon-α2b.
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http://www.translational-medicine.com/content/11/1/38hope of producing additive or synergistic effects was disap-
pointing and the single-agent chemotherapy with dacarba-
zine was found the treatment with the highest response
rate in our series. These findings are consistent with previ-
ous studies in which different combination chemotherapy
schedules have failed to show superiority in terms of
OS compared with dacarbazine alone. In a systematic re-
view of 41 randomised studies in disseminated malignantFigure 3 Overal survival univariate analyses of the effect of Fotemust
subgroups of patients. The area of each square is proportional to the size
the hazard ratio estimates.melanoma, the only advantage over dacarbazine observed
with some combination chemotherapy schedules was an in-
crease in response rate [22].
Regarding our study, It should be noted that fotemustine
was given every three weeks, rather than being adminis-
tered at the usual schedule that includes an induction phase
(weekly for three weeks) followed by a maintenance phase
(same dosage every 3 weeks, 4–6 weeks after the inductionine (FM, left panel) and Interferon-α2b (IFN, right panel) within
of the subgroup; horizontal lines depict 95% confidence intervals of
Table 3 Worst degree of toxic events
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3(5) - - - 60
(90)
4(6) 1(2) - - 66
(92)
3(4) - - - 46
(89)
- - - - 0.156 0.604 0.960 0.243
Stomatitis 57
(92)
2(3) - - - 63
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2(3) - - - 65
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- - - - 69
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1(2) - - - 69
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- - - - 46
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- - - - 0.340 0.604 0.287 0.243
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(89)
- - - - - 0.604 - 0.243
Fever 58
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metastases usually excluded from other trials on metastatic
melanoma.
This trial was designed and initiated in 2002, before
clinical breakthroughs represented by targeted therapies
and immunotherapeutic approaches have revolutionized
the treatment of advanced melanoma. Indeed, both
ipilimumab (a fully human monoclonal antibody that
blocks CTLA-4 to promote antitumor immunity) and
vemurafenib (a potent inhibitor of mutated V600E
BRAF) have been recently approved in Europe and the
US for the treatment of metastatic melanoma. Com-
pared with dacarbazine, ipilimumab has been shown
to improve OS in a randomized trial in patients with
previously treated metastatic melanoma [23], while vemur-
afenib improved OS and PFS in a randomized trial in
patients with previously untreated melanoma harboring theV600 BRAF mutation [24]. Further positive results with ipi-
limumab were shown in another randomized trial, in which
OS was significantly longer in treatment-naïve patients with
advanced melanoma treated with dacarbazine plus ipilimu-
mab compared with dacarbazine plus placebo (11.2 months
vs 9.1 months) [25].
In addition, ipilimumab has also been assessed in com-
bination with fotemustine in the NIBIT-M1 trial [26], a
phase II open-label, single-arm study involving patients
with unresectable stage III or IV cutaneous melanoma. The
main endpoint of the study was to assess the immune-
response disease control rate (irDCR: CR, PR or SD) using
immune-related tumor response criteria [27]. A total of 86
patients, 20 of whom had brain metastases, were enrolled
in this trial. IrDCR was 46.5% (95% CI, 35.7−57.6%), 1-year
OS rate was 52.6% (95% CI, 41.8−63.4), and median OS
was 13.3 months (95% CI, 8.9−19.9). These preliminary
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fotemustine is effective and safe in patients with melanoma,
although this needs to be confirmed in a randomized trial.
Considering the promise of combination therapy with
dacarbazine plus ipilimumab [25] and fotemustine plus ipi-
limumab [26], the addition of ipilimumab to the combin-
ation of fotemustine with dacarbazine could theroretically
represent a potential therapeutic option that could benefit
from any synergistic effect of the combination chemother-
apy (dacarbazine plus fotemustine) as evidenced in our pre-
vious phase II studies [18,19]. Unfortunately, our results in
the phase III study do not support this hypothesis. The
combination of chemotherapy with the BRAF inhibitors
(vemurafenib, dabrafenib) still needs to be investigated.
Recent advances in treatments have suggested new strat-
egies for designing rational therapeutic combinations for
metastatic melanoma. The combination of vemurafenib
and ipilimumab is currently being tested in phase I, as the
combination of ipilimumab and anti-PD1, while the com-
bination of BRAF and MEK inhibitors is the most promis-
ing treatment for the BRAF-mutated population. In fact,
data recently presented [28] showed a PFS of 10.8 months
in V600 BRAF-mutant patients receiving dabrafenib plus
trametinib. This combination is now being tested in a phase
III trial versus vemurafenib in BRAF-mutated patients with
metastatic melanoma (NCT01400451).
The treatment of melanoma has the potential to become
a model for cancer therapy. An approach similar to HIV
treatment, using drugs with different mechanisms of action,
for example acting on the MAPK pathway, PI3K-mTOR
pathway, apoptosis pathway and immunological monoclo-
nal antibodies, could be considered. A combination ap-
proach could consider novel agents together with standard
chemotherapy agents. Sequential administration of different
agents may inhibit cancer cell growth at different check
points, while other agents may inhibit neo-angiogenesis,
survival of malignant cells or metastatization [29].Conclusions
The addition of either fotemustine or α2b to dacarbazine
failed to produce any improvement in outcomes in this
study. Considering the promising results of recent trials
with targeted therapies and/or immunomodulating anti-
bodies in metastatic melanoma, it seems anachronistic
and unwarranted to further investigate combination
chemotherapy compared with single agent chemotherapy
in these patients.
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